ClinicalTrials.gov
ClinicalTrials.gov Menu

Transfusion of Biotin-Labeled Red Blood Cells

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03364686
Recruitment Status : Not yet recruiting
First Posted : December 6, 2017
Last Update Posted : September 11, 2018
Sponsor:
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Michael Risbano, University of Pittsburgh

Brief Summary:
The purpose of this research is to evaluate the impact of genetic and biologic factors in blood donors on red blood cell storage stability after autologous transfusion over the different range of storage period of 5-7 days and 35-42 days in healthy volunteers.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Biological: Biotin-Labeled Red Blood Cells Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 125 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Transfusion of Biotin-Labeled Red Blood Cells for the Evaluation of Genetic Factors That Contribute to Donor Differences in Red Blood Cell Storage and Post-Transfusion Red Blood Cell Recovery
Estimated Study Start Date : October 2018
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2024

Resource links provided by the National Library of Medicine

Drug Information available for: Biotin

Arm Intervention/treatment
Experimental: Biotin-Labeled Red Blood Cells Infusion
Each participant will receive 2 transfusions of biotin labeled red blood cells.
Biological: Biotin-Labeled Red Blood Cells
We will collect 500 mL of blood. The blood will be processed and split into two bags and labeled with a naturally occurring vitamin, biotin. The blood will then be re-infused back into the same participant at 2 time points (5-7 days and 35-42 days after storage).




Primary Outcome Measures :
  1. Length of time biotin-labeled RBCs can be detected following infusion [ Time Frame: up to 165 days ]
    This will be determined using enumeration of biotinylated RBCs obtained by flow cytometry from blood samples obtained at various time points from subjects with specified genetic mutations, compared with control subjects without the specified mutation.


Secondary Outcome Measures :
  1. The percentage of storage hemolysis [ Time Frame: 5-7 days and 35-42 days following blood donation ]
    This will be quantified as percent hemolysis, which accounts for the levels of RBC-derived free hemoglobin in response to cold storage. We will define the associations between the primary endpoints and the quantification of storage hemolysis.

  2. The percentage of red blood cell osmotic hemolysis [ Time Frame: 5-7 days and 35-42 days following blood donation ]
    This will be quantified by the evaluation of osmotic stress assays. We will define the associations between the primary endpoints and the quantification of osmotic hemolysis.

  3. The percentage of red blood cell oxidative hemolysis [ Time Frame: 5-7 days and 35-42 days following blood donation ]
    This will be quantified by the evaluation of oxidative stress assays. We will define the associations between the primary endpoints and the quantification of oxidative hemolysis.

  4. Number of Membrane microvesicle formation [ Time Frame: 5-7 days and 35-42 days following blood donation ]
    This will be quantified by centrifugation and collection of supernatants from stored red blood cell units.

  5. Percentage of biotin labeled red blood cells [ Time Frame: 24 hours following blood transfusion ]
    This will be determined as the percentage of biotin-labeled cells remaining in the circulation 24 hours after transfusion relative to the 20-minute post-infusion blood sample.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age 18-65 years old
  • Weight >110 lbs
  • Hemoglobin ≥ 12.5 g/dL for women and ≥ 13.0 g/dL or hematocrit ≥ 39% for men.
  • Meet criteria for autologous blood donation

Exclusion Criteria:

  • Subjects with a past medical history or symptoms of blood dyscrasia, diabetes mellitus, hyperlipidemia, obstructive sleep apnea, renal disease, congestive heart failure, significant cardiac disease and / or known peripheral arterial disease.
  • Moderate to severe systemic hypertension, BP >140/95 mmHg
  • Systolic blood pressure <100 mmHg and/or diastolic blood pressure < 60 mmHg on the study day.
  • Positive Direct Antiglobulin Test
  • Consumption of biotin supplements or raw eggs within 30 days
  • Treatment with antibiotics in the week before initiating study participation to avoid suppression of erythropoiesis, which may accompany infection.
  • Blood loss in the previous 8 weeks due to epistaxis, trauma, hemoptysis, gastrointestinal bleeding, diagnostic phlebotomy (> 30 ml)
  • Subjects who report tobacco or marijuana smoking within 6 months of study.
  • Cognitively impaired subjects, or institutionalized persons and subjects unable or unwilling to complete written informed consent
  • Subjects with a history of blood donation within the last 56 days.
  • Use of other investigational drugs/devices within 30 days of screening.
  • Subjects taking any medication for the treatment of diabetes including oral hypoglycemics or insulin
  • Females of childbearing potential who are pregnant or unwilling to undergo pregnancy testing; females with positive pregnancy testing on screening day will be excluded.
  • History of prior transfusion reaction to blood products.
  • Allergic reaction to biotin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03364686


Contacts
Contact: Nicole Helbling, RN, BSN, MS 412-692-2285 nlr8@pitt.edu

Sponsors and Collaborators
Gladwin, Mark, MD
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Principal Investigator: Michael Risbano, MD University of Pittsburgh

Responsible Party: Michael Risbano, Assistant Professor of Medicine, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT03364686     History of Changes
Other Study ID Numbers: PRO16110442
5R01HL098032-09 ( U.S. NIH Grant/Contract )
First Posted: December 6, 2017    Key Record Dates
Last Update Posted: September 11, 2018
Last Verified: September 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Michael Risbano, University of Pittsburgh:
BioRBCs
Biotin labeled red blood cells

Additional relevant MeSH terms:
Biotin
Vitamin B Complex
Vitamins
Micronutrients
Growth Substances
Physiological Effects of Drugs